Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... Calif. and DUBAI, United Arab Emirates, Feb. 10, 2011 ... Masimo (Nasdaq: ... Hospital to Masimo rainbow® SET Pulse CO-Oximetry™ technology for ... Hospital the first hospital in the UAE to feature ...
... Some drug manufacturers are aggressively pushing legislative proposals ... would undermine electronic prescribing,s (e-prescribing) proven safety and ... said today. "This campaign undermines ... reducing prescription drug costs. Doctors should be able ...
Cached Medicine Technology:Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 2Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 3Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 4Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 5Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 6Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 7PCMA: Some Drugmakers Lobbying to Limit E-Prescribing of Generics, Drug Safety Checks 2
(Date:7/31/2014)... Joseph M. Lee, M.D., M.S., R.P.V.I, ... a leading provider of quality cardiovascular and internal medicine ... Dr. Lee is a board certified cardiologist with a ... addition to his position at CDHV, Dr. Lee is ... Columbia University Medical Center. Dr. Lee is board certified ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Women in ... take charge of their financial future. The Independent ... has opened registration for 6 upcoming Los Angeles area ... for women, and with input from Kim Kiyosaki, a ... It’s Rising Time) who is passionate about women’s financial ...
(Date:7/31/2014)... steadily in the U.S in recent years. According to ... number of individuals reporting past year heroin use almost ... suggests the increase may be linked to prescription opioid ... use to heroin use, with POs providing the entryway ... This drug-use trajectory appears to have become increasingly common ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... Reinberg HealthDay Reporter THURSDAY, ... rather than war experiences, are a source of drinking problems ... study suggests. Setbacks such as job loss, divorce and ... make as many as 13 percent of vets turn to ... has an important effect on mental health in the short ...
Breaking Medicine News(10 mins):Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3
... Americans with muscular dystrophy die 10 to 12 years younger ... Sept. 14 issue of Neurology , the medical journal ... gap, which was calculated on the basis of 20 years ... annals of research into racial disparities in health care, say ...
... Colorado at Boulder study sheds light on the brain mechanisms ... helpful in improving treatments for the millions of people who ... study, CU-Boulder psychology Professor Yuko Munakata and her research colleagues ... nerve cell suppresses activity in another, is a critical aspect ...
... National Hispanic Science Network on Drug Abuse awarded the ... Investigator to Alice Cepeda, sociology professor and associate director ... Graduate College of Social Work, University of Houston. ... annual conference in New Orleans. , The National ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... levels of thimerosal, a mercury-laden preservative that used to be ... autism than infants exposed to only a little thimerosal, new ... who worry that vaccination raises their children,s risk for autism, ...
... 13 (HealthDay News) -- Women can be vulnerable to ... part of a condition called preeclampsia. And now ... which women are most prone to preeclampsia in late ... relies on so-called "metabolic profiling" to track telltale metabolites ...
... mental aging reveals a good news-bad news situation. The bad ... to varying degrees. The good news is the drops are ... study published by the American Psychological Association. "There ... called crystallized intelligence decline at older ages," said study author ...
Cached Medicine News:Health News:Blacks with muscular dystrophy die 10-12 years younger than whites: New study 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 3Health News:University of Houston researcher receives National Award of Excellence in Research 2Health News:More Evidence That Vaccines Don't Cause Autism 2Health News:More Evidence That Vaccines Don't Cause Autism 3Health News:Test Might Spot Women at High Risk for Pregnancy Complication 2Health News:Test Might Spot Women at High Risk for Pregnancy Complication 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: